4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received a consensus rating of “Buy” from the ten research firms that are presently covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $45.63.

A number of equities analysts have issued reports on FDMT shares. BMO Capital Markets decreased their price objective on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, April 1st. Royal Bank of Canada boosted their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Jefferies Financial Group raised their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Barclays assumed coverage on 4D Molecular Therapeutics in a research report on Monday, April 15th. They issued an “overweight” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, June 7th.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 8,153 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total transaction of $259,102.34. Following the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $55,201.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 17,486 shares of company stock valued at $553,073. 7.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth $142,000. Aigen Investment Management LP bought a new position in 4D Molecular Therapeutics in the third quarter valued at about $216,000. Healthcare of Ontario Pension Plan Trust Fund boosted its position in 4D Molecular Therapeutics by 4.3% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 348,700 shares of the company’s stock worth $4,439,000 after purchasing an additional 14,400 shares during the last quarter. Peloton Wealth Strategists bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $318,000. Finally, Trexquant Investment LP purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $566,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $22.78 on Friday. 4D Molecular Therapeutics has a 1 year low of $9.44 and a 1 year high of $36.25. The company’s 50-day moving average is $25.08 and its 200 day moving average is $24.36. The stock has a market capitalization of $1.18 billion, a P/E ratio of -9.34 and a beta of 2.89.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.07. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.44 million. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. Research analysts anticipate that 4D Molecular Therapeutics will post -2.98 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.